Market Closed -
Nasdaq
01:30:00 11/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.7855
USD
|
-3.78%
|
|
-1.57%
|
+15.55%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,370
|
802.5
|
463.8
|
75.22
|
87.71
|
-
|
-
|
Enterprise Value (EV)
1 |
2,014
|
554.3
|
265.4
|
75.22
|
-41.05
|
-132
|
-119.5
|
P/E ratio
|
-14.8
x
|
-4.72
x
|
-2.33
x
|
-0.37
x
|
-2.17
x
|
-2.22
x
|
-1.71
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-28.3
x
|
-3.27
x
|
-1.56
x
|
-0.38
x
|
0.77
x
|
2.4
x
|
-
|
EV / FCF
|
-33
x
|
-5.21
x
|
-1.87
x
|
-
|
0.91
x
|
-
|
-
|
FCF Yield
|
-3.03%
|
-19.2%
|
-53.5%
|
-
|
110%
|
-
|
-
|
Price to Book
|
7.09
x
|
3.65
x
|
2.13
x
|
-
|
0.75
x
|
0.46
x
|
0.49
x
|
Nbr of stocks (in thousands)
|
61,660
|
62,014
|
90,416
|
1,10,653
|
1,11,658
|
-
|
-
|
Reference price
2 |
38.44
|
12.94
|
5.130
|
0.6798
|
0.7855
|
0.7855
|
0.7855
|
Announcement Date
|
11/02/21
|
10/02/22
|
15/02/23
|
15/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.165
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-71.24
|
-169.6
|
-170.5
|
-199.5
|
-53.43
|
-55.01
|
-
|
EBIT
1 |
-
|
-71.31
|
-169.8
|
-171.2
|
-199.9
|
-60.1
|
-67.26
|
-59.38
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-69.78
|
-171
|
-169
|
-190.5
|
-41
|
-78.57
|
-53.88
|
Net income
1 |
-23.84
|
-69.78
|
-172
|
-168.7
|
-190.4
|
-41.63
|
-41.1
|
-53.88
|
Net margin
|
-14,447.88%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-12.44
|
-2.590
|
-2.740
|
-2.200
|
-1.830
|
-0.3628
|
-0.3533
|
-0.4600
|
Free Cash Flow
1 |
-
|
-61.05
|
-106.3
|
-142.1
|
-
|
-45
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
03/06/20
|
11/02/21
|
10/02/22
|
15/02/23
|
15/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-45.46
|
-55.7
|
-
|
-44.54
|
-42.86
|
-40.35
|
-
|
-47.22
|
-46.88
|
-62.26
|
-22
|
-11
|
-5
|
-3
|
-
|
EBIT
1 |
-45.5
|
-55.8
|
-43.19
|
-44.62
|
-42.95
|
-40.43
|
-43.23
|
-47.3
|
-46.96
|
-69.18
|
-22
|
-11
|
-5
|
-3
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-45.51
|
-56.93
|
-43.86
|
-44.49
|
-42.07
|
-38.55
|
-41.18
|
-45.27
|
-44.27
|
-59.82
|
-22
|
-11
|
-5
|
-3
|
-
|
Net income
1 |
-45.51
|
-57.94
|
-43.86
|
-44.64
|
-42.07
|
-38.14
|
-41.18
|
-45.27
|
-44.27
|
-59.82
|
-19.38
|
-11.38
|
-9.381
|
-8.714
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.7200
|
-0.9200
|
-0.6900
|
-0.6900
|
-0.5000
|
-0.3700
|
-0.4400
|
-0.4800
|
-0.3900
|
-0.5300
|
-0.1706
|
-0.0986
|
-0.0826
|
-0.0746
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
05/11/21
|
10/02/22
|
05/05/22
|
04/08/22
|
03/11/22
|
15/02/23
|
04/05/23
|
03/08/23
|
02/11/23
|
15/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
356
|
248
|
198
|
-
|
129
|
220
|
207
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-61
|
-106
|
-142
|
-
|
-45
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-29.4%
|
-59.5%
|
-75%
|
-
|
-39.5%
|
-35.8%
|
-26.2%
|
ROA (Net income/ Total Assets)
|
-
|
-27.4%
|
-52.3%
|
-59.9%
|
-
|
-24%
|
-
|
-
|
Assets
1 |
-
|
255.1
|
328.7
|
281.8
|
-
|
173.6
|
-
|
-
|
Book Value Per Share
2 |
-
|
5.420
|
3.540
|
2.410
|
-
|
1.050
|
1.710
|
1.610
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
-
|
0.1000
|
0.3600
|
-
|
Capex
|
-
|
0.24
|
0.03
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
03/06/20
|
11/02/21
|
10/02/22
|
15/02/23
|
15/03/24
|
-
|
-
|
-
|
Mean consensus UNDERPERFORM Last Close Price
0.7855
USD Average target price
1
USD Spread / Average Target +27.31% Consensus |
1st Jan change
|
Capi.
|
---|
| +15.55% | 87.71M | | +3.91% | 109B | | +10.87% | 105B | | +1.28% | 22.25B | | -13.14% | 22.09B | | -7.05% | 18.68B | | -38.36% | 17.58B | | -10.66% | 16.85B | | +3.75% | 13.76B | | +36.70% | 12.46B |
Bio Therapeutic Drugs
|